The Medical Letter on Drugs and Therapeutics
A Betamethasone-Calcipotriene Combination for Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Taclonex ointment (Warner Chilcott/LEO Pharma), a combination of the vitamin D3 analog calcipotriene 0.005% (Dovonex) and the high-potency corticosteroid betamethasone dipropionate 0.064%, was recently approved by the FDA for treatment of psoriasis vulgaris in patients ≥18 years old.

BACKGROUND — Topical corticosteroids are the mainstay of treatment for psoriasis. When used alone, calcipotriene (called calcipotriol outside the US) is about as effective in treating psoriasis as a medium-potency steroid.1 When calcipotriene is used in combination with a potent topical corticosteroid, each applied once a day at different times, efficacy is better than treatment with either one alone. Calcipotriene is inactivated by acid pH and may not be stable when applied with some other topical products.2

CLINICAL STUDIES — A double-blind study in ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: A Betamethasone-Calcipotriene Combination for Psoriasis
Article code: 1238c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian